Skip to content
MarketScale
‹ Back to IndustriesSciences

The Fungus from The Last of Us Could Help Fight Cancer

The Last of Us, HBO’s videogame-inspired zombie TV epic, opened to rave reviews last month. This drama, led by Game of Thrones stars Pedro Pascal and Bella Ramsey, shows a post-apocalyptic world that has been ravaged by the corydceps fungus after the fungus adapts for survival in the human body. Scarily enough, the fungus from…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Leslie Samuel · Cancer ResearchCordyceps FungusFungiMycology
Share

Key takeaways

01

The Last of Us, HBO’s videogame-inspired zombie TV epic, opened to rave reviews last month.

02

This drama, led by Game of Thrones stars Pedro Pascal and Bella Ramsey, shows a post-apocalyptic world that has been ravaged by the corydceps fungus after the fungus adapts for survival in the human body.

03

Scarily enough, the fungus from…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

The Last of Us, HBO’s videogame-inspired zombie TV epic, opened to rave reviews last month. This drama, led by Game of Thrones stars Pedro Pascal and Bella Ramsey, shows a post-apocalyptic world that has been ravaged by the corydceps fungus after the fungus adapts for survival in the human body. Scarily enough, the fungus from The Last of Us is very, very real, and it’s turned many more casual eyes to the world of mycology. Should people give the cordyceps fungus the horror treatment, though?

Cordyceps’ claim to fame isn’t off base; some species of the fungus are known to infect insects and basically, turn them into zombies. Interest in the series has raised questions of whether a cordyceps-fueled pandemic can actually threaten humanity. Experts in the field of mycology say it is highly improbable and would require major genetic changes, which would probably develop over the course of millions of years.

Although the fungus may be terrifying for invertebrates, outside of The Last of Us’s lore, cordyceps is actually quite useful for humans. It is a widely used ingredient in traditional Chinese medicine, and recent research shows it may even have anti-cancerous properties. So as media consumers clamor for cordyceps content, how is the science community approaching research around the zombie fungus? Leslie Samuel, founder of Interactive Biology, a Master’s in Neurobiology holder, and an experienced science educator, breaks down some of the most recent research surrounding the fungus from The Last of Us.

Leslie’s Thoughts:

“In the field of mycology, which is the study of fungi, there’s been a lot of interest in the cordyceps fungus. That’s the same type of fungus that the show, The Last of Us, is based on. We know that certain species of that fungus can infect ants, turning them into zombies, and when they get infected, those ants will climb up a tree and bite into it, basically committing suicide as the fungus takes over their bodies and [causes] them to release more spores so that they can infect more ants. And the cycle continues like in The Last of Us, but with ants.

But there are also studies that show that certain species of the cordyceps fungus have potential anti-cancer effects. They’ve demonstrated that certain extracts from some species of the cordyceps fungus seems to inhibit the growth of liver cancer. And other studies suggest that there are specific substances in some species that inhibit the inflammatory response in certain immune system cells in mice. Now, there’s still a lot more research that needs to be done to confirm that these effects can actually help in therapies in the future. But this entire field of mycology is fascinating, with these fungi having both harmful and potentially life-saving properties.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Leslie Samuel

Leslie Samuel's journey is a testament to determination and passion. Although his dream of becoming a university professor was initially hampered by the lack of a Ph.D., he didn't let that stop him. Instead, he embraced the digital age, becoming a prominent blogger and YouTuber. Through these platforms, Leslie shared his knowledge, effectively teaching what he would have taught in a classroom, reaching hundreds of thousands of eager learners worldwide. His online success opened doors, leading to his dream job as a university professor in a Doctor of Physical Therapy program, despite the absence of a Ph.D. However, Leslie's impact online was undeniable, prompting him to make the bold decision to transition into a full-time blogger and business coach. Today, through Interactive Biology, Leslie Samuel continues to demonstrate that Biology is not only educational but also immensely enjoyable. His journey is a shining example of how determination and innovation can turn dreams into reality.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte's 2024 report, covered by TechTarget in April 2024, estimated that a top-10 biopharma company could capture $5-7 billion in peak AI value over five years, with about 90% concentrated in R&D, manufacturing/supply chain, and commercial functions. McKinsey reported in November 2025 that despite rising AI investment, pharma companies have not yet seen shorter development timelines or better clinical success rates.

  • 01Deloitte estimates $5–7B peak AI value for top-10 biopharma firms over five years, with cost reductions appearing in 1–2 quarters and revenue gains taking 3–4 quarters.
  • 02McKinsey found pharma companies have not yet achieved shorter drug development timelines or improved preclinical and clinical success rates despite increased AI spending.
  • 03AI systems used in manufacturing, supply chain, and R&D functions may require validation under existing regulated systems frameworks like GAMP.

Sep 13, 2026

CPC Biotech, Multiply Labs Develop Robot-Ready Cell Therapy Connector

CPC Biotech, Multiply Labs Develop Robot-Ready Cell Therapy Connector

CPC Biotech, part of PSG and Dover, announced on May 27, 2026 that it is collaborating with Multiply Labs to develop an aseptic connector designed for robotic operation. The companies said the connector combines CPC's MicroCNX Nano Series with a proprietary interface engineered for robotic grippers, giving robots a consistent contact point during aseptic fluid transfers in Multiply Labs' closed cell and gene therapy processing systems.

  • 01Robotic grippers can reliably handle rigid parts but struggle with soft materials like bags and tubing, driving demand for robot-compatible connectors in sterile processing.
  • 02Commercial cell therapy production was under 5,000 doses per year in 2023 while global demand was estimated in the millions, creating manufacturing constraints.
  • 03Cell therapy manufacturing may involve upwards of 40 process steps, and optimal workflows remain under development without industrywide standardization.

Sep 10, 2026

Lab automation ROI hinges on integration, not instrument sensitivity claims

Lab automation ROI hinges on integration, not instrument sensitivity claims

At ADLM 2026, Waters and LabCollector delivered a clear message for lab leaders: the limiting factor in automation is often integration, not hardware. Waters introduced the Xevo TQ Absolute XR IVD mass spectrometer and is positioning it at “5x greater sensitivity” versus in-class instruments, according to SelectScience, but that advantage only carries through if sample prep, calibration and QA, middleware rules, and LIMS result review can keep pace. In parallel, LabCollector announced an AI Co-Scientist feature set for natural-language search, knowledge retrieval, and AI-assisted content creation inside ELN and LIMS workflows, also reported by SelectScience, shifting attention from pipetting speed to retrieval, approval, permissions, and versioning in systems that sit on the documentation path. The Scientist’s overview of semi-automated versus fully automated approaches reinforces the point: labs can automate in modules, but they have to run automation as one system.

  • 01The bottleneck in automation is often the handoff, instrument to middleware to LIMS, so sensitivity and throughput gains depend on interfaces and downstream review as much as the instrument spec.
  • 02Waters’ “5x greater sensitivity” positioning and LabCollector’s AI Co-Scientist both point to integration work, sample prep, calibration and QA, middleware rules, and LIMS result review, as the gating factor for ROI.
  • 03As ELN/LIMS add conversational search and AI-assisted content creation, speed gains move from pipetting to retrieval, approval, permissions, and versioning inside systems that sit in regulated or audited workflows.

Sep 3, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Leslie Samuel's journey is a testament to determination and passion. Although his dream of becoming a university professor was initially hampered by the lack of a Ph.D., he didn't let that stop him. Instead, he embraced the digital age, becoming a prominent blogger and YouTuber. Through these platforms, Leslie shared his knowledge, effectively teaching what he would have taught in a classroom, reaching hundreds of thousands of eager learners worldwide. His online success opened doors, leading to his dream job as a university professor in a Doctor of Physical Therapy program, despite the absence of a Ph.D. However, Leslie's impact online was undeniable, prompting him to make the bold decision to transition into a full-time blogger and business coach. Today, through Interactive Biology, Leslie Samuel continues to demonstrate that Biology is not only educational but also immensely enjoyable. His journey is a shining example of how determination and innovation can turn dreams into reality.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512